SRR1435753
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.421
- INTERFERON_GAMMA_RESPONSE+0.407
- ALLOGRAFT_REJECTION+0.374
- TNFA_SIGNALING_VIA_NFKB+0.362
- INTERFERON_ALPHA_RESPONSE+0.354
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- KRAS_SIGNALING_DN+0.343
- IL2_STAT5_SIGNALING+0.297
- BILE_ACID_METABOLISM+0.283
Top 10 suppressed
- DNA_REPAIR-0.487
- MYC_TARGETS_V1-0.461
- MYC_TARGETS_V2-0.438
- UNFOLDED_PROTEIN_RESPONSE-0.387
- E2F_TARGETS-0.349
- G2M_CHECKPOINT-0.333
- WNT_BETA_CATENIN_SIGNALING-0.331
- NOTCH_SIGNALING-0.296
- MITOTIC_SPINDLE-0.293
- TGF_BETA_SIGNALING-0.217
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1254 | Med | Medulloblastoma | 0.922 |
| 2 | SRR1499630 | GTEX | — | 0.922 |
| 3 | ERR2598319 | fetal | fetal | 0.922 |
| 4 | SRR1079591 | GTEX | — | 0.918 |
| 5 | SRR1444622 | GTEX | — | 0.902 |
| 6 | SRR607647 | GTEX | — | 0.896 |
| 7 | SRR1416889 | GTEX | — | 0.892 |
| 8 | SRR1472150 | GTEX | — | 0.892 |
| 9 | SRR607406 | GTEX | — | 0.891 |
| 10 | ERR2598268 | fetal | fetal | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.421 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.407 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.374 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.362 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.354 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.343 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.297 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.283 | Inavolisib | — uncovered |
| COMPLEMENT | 0.279 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.243 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.242 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.231 | Idelalisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| MYOGENESIS | 0.212 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.201 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.191 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.161 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.149 | Inavolisib | — uncovered |